MedTrace Logo

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

NCT01829477 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2016-06-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

TAK-875

TAK-875 50 mg tablets

DRUG

TAK-875 Placebo

TAK-875 placebo-matching tablets

DRUG

Glimepiride

Glimepiride tablet.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States
  • Bulgaria
  • Canada
  • Hungary
  • Poland
  • Romania
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01829477 on ClinicalTrials.gov